A novel treatment for limited mouth opening due to facial fibrosis: A case series
To the Editor: Limited mouth opening (LMO) is a frequent consequence of progressive facial fibrosis due to systemic sclerosis (SSc) and other connective tissue diseases. LMO affects the daily lives of patients by altering their physical appearance and impairing their ability to eat and phonate. LMO can also have a significant impact on the health of patients by making it difficult for them to perform regular dental hygiene and undergo dental examinations. Current treatment options are few and of low efficacy and reliability. 1 Our first patient presented 3 years ago with LMO as a result of SSc, and her initial oral aperture was 3.0 cm. She had previously received perioral botulinum toxin A (BTX-A) for cosmetic treatment of rhytids and serendipitously noticed decreased constriction of her oral aperture. Given this observation, the patient was initially treated conservatively with 1.25 units of BTX-A in 4 perioral sites, and an improvement in constriction was again noted. Over the next 2 years, the procedure was refined to 2.5 units of BTX-A in 8 evenly spaced sites as shown in Fig 1; the patient's oral aperture has increased to 4.5 cm. Over the last year, we have treated an additional 4 patients; their characteristics are summarized in Table I .
The mechanisms by which BTX-A improves LMO are uncertain but are thought to involve its effects on muscles and fibroblasts. BTX-A has well known paralytic effects that when applied to the orbicularis oris, likely reduces that muscle's ability to oppose mouth opening. Additionally, 2 in vitro studies showed that BTX-A has notable effects on fibroblasts, which are thought to be the effector cells in SSc. 2 In particular, the studies suggested that BTX-A decreased differentiation of fibroblasts to myofibroblasts, decreased expression of collagen types 1 and 3, and increased expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. 3, 4 These changes effectively counteract the derangements seen in skin samples from patients with SSc: increased differentiation of fibroblasts to myofibroblasts, increased extracellular matrix deposition, and decreased matrix metalloproteinase 1.
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Perioral BTX-A has been shown to be safe for treatment of rhytids, and to date, there have been no significant adverse events with its use for LMO. Oral apertures increased from 0.5 to 2.0 cm and there were associated quality-of-life and health benefits. Patients reported increased confidence thanks to a wider smile and greater enjoyment of meals thanks to less food restriction. Patients also found dental visits and procedures more comfortable and intubations for surgical procedures more tolerable. These benefits were noticed in 4 to 7 days and began to wane after 2 to 3 months. Patients 1, 3, 4, and 5 are pleased with their results and plan to continue getting treatments. Patient 2 had improvement of LMO but was more distressed by her decreased ability to purse her lips; she has deferred further treatment at this time. Although the exact mechanism of action is unknown and further research is needed, our initial series suggests that perioral BTX-A is a reasonable treatment for LMO due to skin fibrosis. To the Editor: Localized chronic pruritus is a common condition that significantly affects health-related quality of life. A variety of diseases result in localized chronic itch, which can be broadly classified as dermatologic, neuropathic, or psychogenic in nature. For patients with chronic pruritus that is refractory to conventional therapy, the burden of disease is substantial.
Current management is directed at the underlying cause, with the majority of cases of localized chronic itch being nonhistaminergic in etiology. Treatment typically begins with nonpharmacologic therapies, adding topical glucocorticoids, topical anesthetics, coolants, topical calcineurin inhibitors, and intralesional corticosteroids in a stepwise approach.
Botulinum toxin type A (BoNT/A) is a neurotoxic protein approved by the US Food and Drug Administration for the treatment of glabellar and periorbital wrinkles, severe primary axillary hyperhidrosis, and numerous neurologic indications. 1 BoNT/A has shown potential in the medical literature as an antipruritic agent for patients with localized, chronic pruritus that is refractory to conventional therapies. BoNT/A is believed to reduce pruritic symptoms by dulling the transmission of C fiber itch signals; it may also have an effect on small fiber neuropathies by altering transmission of neural input from the peripheral nervous system. 2 We conducted a review of the current literature using the PubMed database to evaluate the use of intradermal BoNT/A in treating various types of localized chronic itch. Our search included English language articles containing the words ''botulinum'' and ''itch'' published before November 2016. We found 25 studies containing these key words dating from 1996 to 2016. Eleven articles that focused on the use of intradermal BoNT/A for the treatment of chronic refractory pruritus were included (Table I) . The Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow chart is shown in Fig 1. The grade of recommendation for each study was determined using the Oxford Centre for Evidence-based Medicine Levels of Evidence (Table I) .
Overall, these studies suggest the potential for BoNT/A to relieve symptoms in patients with localized chronic itch caused by brachioradial pruritus, lichen simplex, partial-to full-thickness burns, inverse psoriasis, and HaileyeHailey disease that are refractory to conventional therapy. Of note, the use of BoNT/A in treating pruritus caused by notalgia and meralgia paresthetica seems to have less consistent results, with some patients reporting significant 
